US 12,291,750 B2
Predictive and prognostic use of a miRNA for high grade serous ovarian carcinoma therapeutic care
Nicolas Vigneron, Douvres la Delivrande (FR); Christophe Denoyelle, Saint-Germain-sous-Cailly (FR); Laurent Poulain, Thue et Mue (FR); Jean-Paul Issartel, Saint-Egreve (FR); Bernard Lambert, Cabourg (FR); Matthieu Meryet-Figuiere, Caen (FR); Mégane Vernon, Caen (FR); and Audrey Guttin, Saint-Martin-le-Vinoux (FR)
Assigned to UNIVERSITE DE CAEN NORMANDIE, Caen (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); CENTRE REGIONAL FRANCOIS BACLESSE, Caen (FR); and UNIVERSITE GRNOBLE ALPES, Saint-Martin d'Héres (FR)
Appl. No. 17/253,363
Filed by UNIVERSITE DE CAEN NORMANDIE, Caen (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); CENTRE REGIONAL FRANCOIS BACLESSE, Caen (FR); and UNIVERSITE GRENOBLE ALPES, Saint Martin d'Heres (FR)
PCT Filed Jul. 4, 2019, PCT No. PCT/EP2019/068009
§ 371(c)(1), (2) Date Dec. 17, 2020,
PCT Pub. No. WO2020/007988, PCT Pub. Date Jan. 9, 2020.
Claims priority of application No. 18305887 (EP), filed on Jul. 5, 2018; and application No. 18290130 (EP), filed on Nov. 8, 2018.
Prior Publication US 2021/0269883 A1, Sep. 2, 2021
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/178 (2013.01)] 4 Claims
 
1. A method for treating an advanced stage III to IV HGSOC patient in relapse comprising:
administering a conventional platinum-based chemotherapy treatment and/or a PARP inhibitor (PARPi)-based treatment to the HGSOC patient,
wherein the patient has been identified at relapse as sensitive to the conventional platinum-based chemotherapy treatment and/or the PARP inhibitor (PARPi)-based treatment by a method comprising the steps of:
(a) obtaining a liquid biological sample from the HGSOC patient at relapse;
(b) determining at least the concentration of hsa-miR-622 in the liquid biological sample obtained from said HGSOC patient at relapse;
(c) comparing the determined hsa-miR-622 concentration with at least one reference value at relapse,
wherein a determined hsa-miR-622 concentration of lower than 0.34 zmol/μl, identifies the patient as a PARPi-sensitive and/or platinum-sensitive patient.